We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$22.7M
Cap. Flow
+$19.2M
Cap. Flow %
3.83%
Top 10 Hldgs %
48.75%
Holding
84
New
17
Increased
18
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$38.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$14.2M
3
RGEN icon
Repligen
RGEN
+$13.6M
4
GMAB icon
Genmab
GMAB
+$13.3M
5
HNGE
Hinge Health
HNGE
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
2
HUM icon
Humana
HUM
+$13.3M
3
GKOS icon
Glaukos
GKOS
+$13.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
2 Miscellaneous 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
26
Beam Therapeutics
BEAM
$2.58B
$6.96M 1.39%
409,400
-300,117
-42% -$5.23M
HUM icon
27
Humana
HUM
$46.4B
$6.75M 1.34%
27,600
-53,400
-66% -$13.3M
CATX icon
28
Perspective Therapeutics
CATX
$329M
$6.39M 1.27%
1,858,596
-338,674
-15% -$894K
OGN icon
29
Organon & Co
OGN
$3.59B
$6.2M 1.23%
640,000
+105,000
+20% +$1.08M
BBIO icon
30
BridgeBio Pharma
BBIO
$13B
$6.05M 1.2%
140,000
+65,000
+87% +$2.36M
INSM icon
31
Insmed
INSM
$26.2B
$5.94M 1.18%
59,000
-48,000
-45% -$3.67M
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$12.3B
$5.75M 1.15%
+19,000
New +$5.66M
RARE icon
33
Ultragenyx Pharmaceutical
RARE
$1.43B
$5.6M 1.12%
154,000
-168,100
-52% -$6.06M
CNTX icon
34
Context Therapeutics
CNTX
$33.8M
$4.9M 0.98%
7,477,255
+55
+0% +$40
ORKA
35
Oruka Therapeutics
ORKA
$6.29B
$3.95M 0.79%
352,124
– –
IMUX icon
36
Immunic
IMUX
$145M
$3.92M 0.78%
561,581
+116,140
+26% +$1.07M
ARQT icon
37
Arcutis Biotherapeutics
ARQT
$3.19B
$3.76M 0.75%
+268,000
New +$3.76M
DOCS icon
38
Doximity
DOCS
$4.65B
$3.68M 0.73%
60,000
-62,500
-51% -$3.49M
XENE icon
39
Xenon Pharmaceuticals
XENE
$3.85B
$3.38M 0.67%
107,891
-121,109
-53% -$3.95M
VRNA
40
DELISTED
Verona Pharma
VRNA
$3.2M 0.64%
+33,800
New +$2.5M
SNDX icon
41
CALL
Syndax Pharmaceuticals
SNDX
$1.57B
$3.18M 0.63%
340,000
-60,000
-15% -$660K
QURE icon
42
uniQure
QURE
$3.05B
$2.89M 0.57%
207,000
-129,200
-38% -$1.74M
APGE
43
DELISTED
Apogee Therapeutics
APGE
$2.82M 0.56%
+65,000
New +$2.47M
SLNO
44
DELISTED
Soleno Therapeutics
SLNO
$2.68M 0.53%
32,000
– –
CAH icon
45
Cardinal Health
CAH
$52.4B
$2.52M 0.5%
+15,000
New +$2.23M
SPRY icon
46
ARS Pharmaceuticals
SPRY
$409M
$2.44M 0.49%
+140,000
New +$2.02M
KZR
47
DELISTED
Kezar Life Sciences
KZR
$2.3M 0.46%
502,600
– –
NTLA icon
48
Intellia Therapeutics
NTLA
$1.7B
$2.18M 0.43%
+232,000
New +$1.91M
MLTX icon
49
MoonLake Immunotherapeutics
MLTX
$1.05B
$1.84M 0.37%
+39,000
New +$1.59M
ARVN icon
50
Arvinas
ARVN
$542M
$1.79M 0.36%
243,162
-170,000
-41% -$1.25M
1
2
3 4

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2025 Portfolio in Review

As of Q2 2025, Avidity Partners Management held 84 positions worth $502M, down 4.3% from $525M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Avidity Partners Management deployed $19.2M of net new capital in Q2 2025, opening 17 new positions and adding to 18 existing holdings. Its largest new stake was Jade Biosciences: 1,127,186 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Humana, an estimated $13.3M trimmed.

  • Avidity Partners Management's largest Q2 2025 buy was Jade Biosciences: 1,127,186 shares worth $11.3M.
  • Avidity Partners Management added most to CG Oncology in Q2 2025, an estimated $12.5M increase.
  • Avidity Partners Management's biggest Q2 2025 reduction was Humana, cutting an estimated $13.3M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $16.1M.
  • Avidity Partners Management's ten largest holdings make up 49% of its $502M portfolio in Q2 2025.
  • Avidity Partners Management opened 17 new positions and closed 28 in Q2 2025.
  • Avidity Partners Management's portfolio value fell 4.3% quarter-over-quarter to $502M.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.